Member Info for Rocket79

$100 Billion Liquid Biopsy Market in the US alone.

“Parsortix system is the ONLY liquid Biopsy solution with FDA product clearance for harvesting intact cancer cells from patient blood for analysis”

Now have a re-think on value here.

Massive buy volume.Investors loading up below 30p for the next leg up. Buy

Agree bottom hit. Buy the dips and hold.

Agree this is going to rise from here. Bargain at this price.

Buyers loading up under 30p as it consolidates ready for the next rise.

Directors were buying at 80p and this hit 150p on FDA approval. Patent protected until 2035 in a 100 billion dollar liquid biopsy field.

Tree shake almost over. Get ready for another rise above 35p. 45p finish imo

Buyer loading up under 30p again. 45p finish today.

News was transformational. Buying strength so strong. 45p today, I agree

Expecting more good news before presentation in Lonon next week.

Angle can do 50,000 tests per year in its laboratories and at an average of £1000 per test. Then there is also sales of the machines and ancillary equipment. You do the maths. Truely staggering. Dyor

Volume over 10mil and not even 9am... This is going to hit 45p today

I agree another 100% rise could happen. Directors were buying at 80p and this hit 150p on FDA approval. Patent protected until 2035 in a 100 billion dollar liquid biopsy field.

Buying volume is phenomenal. News still not wide spread. Topped up again. This is going to 80p by end of next week imo

I agree another 100% rise could happen. Directors were buying at 80p and this hit 150p on FDA approval. Patent protected until 2035 in a 100 billion dollar liquid biopsy field.

Buying relentless. Tree shake over, they can't hold this back now. Buy

Buyers hoovering up shares under 30p. Don't sell your share cheap. This will finish Blue today.

Hold. Buyers will be rewarded. Market makers want your shares.

Patent protected until 2035. They are also being granted new patents.

Big Pharma can not ignore this...

Amazing results. Shows power of Parsortix.

"Actionable variants identified in our patient cohort in the CTCs that were not present in the ctDNA included variants targeted by widely used drugs from many large pharma companies, for example:

-- PIK3CA (E545K): Alpelisib (Piqray(R) ) marketed by Novartis

-- EGFR (T790M): Tagrisso (Osimertinib(R) ) marketed by Astra Zeneca

-- ESR1 (K303R): Elacestrant (Oserdu(R) ) marketed by Menarini

-- MTOR (T1977K): Everolimus (Afinitor(R) ) marketed by Novartis

-- ERBB2 (R678Q): Trastuzumab, Pertuzumab, Neratinib, Afatinib marketed respectively by Astra Zeneca, Roche Genentech, Puma Biotechnology, and Boehringer Ingelheim